Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
Bo Åhrén, Stephen L. Atkin, G. Charpentier, et al.
Diabetes Obesity and Metabolism (2018) Vol. 20, Iss. 9, pp. 2210-2219
Open Access | Times Cited: 110

Showing 1-25 of 110 citing articles:

The Discovery and Development of Liraglutide and Semaglutide
Lotte Bjerre Knudsen, Jesper Lau
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 634
Pharmacotherapy of obesity: Available medications and drugs under investigation
Eleni Pilitsi, Olivia M. Farr, Stergios A. Pοlyzos, et al.
Metabolism (2018) Vol. 92, pp. 170-192
Open Access | Times Cited: 229
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
Robert F. Kushner, Salvatore Calanna, Melanie J. Davies, et al.
Obesity (2020) Vol. 28, Iss. 6, pp. 1050-1061
Open Access | Times Cited: 214
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
Vanita R. Aroda, Andrew Ahmann, Bertrand Cariou, et al.
Diabetes & Metabolism (2019) Vol. 45, Iss. 5, pp. 409-418
Open Access | Times Cited: 192
Safety of Semaglutide
Mark M. Smits, Daniël H. van Raalte
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 180
Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery
Francesco Rubino, Ricardo V. Cohen, Geltrude Mingrone, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 8, Iss. 7, pp. 640-648
Open Access | Times Cited: 167
Wegovy (Semaglutide): A New Weight Loss Drug for Chronic Weight Management
Gurdeep Singh, Matthew Krauthamer, Meghan Bjalme-Evans
Journal of Investigative Medicine (2021) Vol. 70, Iss. 1, pp. 5-13
Open Access | Times Cited: 135
A genetic map of the mouse dorsal vagal complex and its role in obesity
Mette Q. Ludwig, Wenwen Cheng, Desiree Gordian, et al.
Nature Metabolism (2021) Vol. 3, Iss. 4, pp. 530-545
Closed Access | Times Cited: 118
Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
Juan José Gorgojo Martínez, Pedro Mezquita‐Raya, Juana Carretero Gómez, et al.
Journal of Clinical Medicine (2022) Vol. 12, Iss. 1, pp. 145-145
Open Access | Times Cited: 112
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Patrick J. Knerr, Stephanie A. Mowery, Jonathan D. Douros, et al.
Molecular Metabolism (2022) Vol. 63, pp. 101533-101533
Open Access | Times Cited: 87
Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
Yamin Shu, Xu‐Cheng He, Pan Wu, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 77
Human trials exploring anti-aging medicines
Leonard Guarente, David Sinclair, Guido Kroemer
Cell Metabolism (2024) Vol. 36, Iss. 2, pp. 354-376
Open Access | Times Cited: 70
Transforming obesity: The advancement of multi-receptor drugs
Christine M. Kusminski, Diego Pérez–Tilve, Timo D. Müller, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3829-3853
Closed Access | Times Cited: 24
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Jens J. Holst
Nature Metabolism (2024) Vol. 6, Iss. 10, pp. 1866-1885
Open Access | Times Cited: 24
Glucagon-like Peptide-1 Receptor Agonists Associated Gastrointestinal Adverse Events: A Cross-Sectional Analysis of the National Institutes of Health All of Us Cohort
Wafa Ali Aldhaleei, Tadesse Melaku Abegaz, Akshaya Srikanth Bhagavathula
Pharmaceuticals (2024) Vol. 17, Iss. 2, pp. 199-199
Open Access | Times Cited: 22
Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes
Janet K. Snell‐Bergeon, Gurleen Kaur, D. Renner, et al.
Diabetes Technology & Therapeutics (2025) Vol. 27, Iss. 1, pp. 1-9
Closed Access | Times Cited: 4
Semaglutide as a promising antiobesity drug
Georgios A. Christou, Niki Katsiki, John E. Blundell, et al.
Obesity Reviews (2019) Vol. 20, Iss. 6, pp. 805-815
Closed Access | Times Cited: 127
A review of GLP‐1 receptor agonists in type 2 diabetes: A focus on the mechanism of action of once‐weekly agents
Susan Cornell
Journal of Clinical Pharmacy and Therapeutics (2020) Vol. 45, Iss. S1, pp. 17-27
Open Access | Times Cited: 100
Bariatric surgery for the treatment of chronic kidney disease in obesity and type 2 diabetes mellitus
Neil G. Docherty, Carel W. le Roux
Nature Reviews Nephrology (2020) Vol. 16, Iss. 12, pp. 709-720
Closed Access | Times Cited: 90
Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
Sean Wharton, Salvatore Calanna, Melanie J. Davies, et al.
Diabetes Obesity and Metabolism (2021) Vol. 24, Iss. 1, pp. 94-105
Open Access | Times Cited: 86
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angeliki M. Angelidi, Matthew J. Belanger, Alexander Kokkinos, et al.
Endocrine Reviews (2021) Vol. 43, Iss. 3, pp. 507-557
Open Access | Times Cited: 81
Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Mathies M. Jepsen, Mikkel Christensen
Expert Opinion on Emerging Drugs (2021) Vol. 26, Iss. 3, pp. 231-243
Closed Access | Times Cited: 71
Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
Xueqin Gao, Xiaoli Hua, Xu Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 53
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Fatma Haddad, Ghadeer Dokmak, Maryam Bader, et al.
Life (2023) Vol. 13, Iss. 4, pp. 1012-1012
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top